A small controlled simulator study found worse lane control after alprazolam and explored an experimental classifier. Its accuracy estimate concerns the study’s driving outcomes, rather than roadside diagnosis.
Stone and colleagues analyzed 19 participants from 24 initially enrolled. Participants completed simulated driving and neurocognitive assessments accompanied by EEG and ECG recordings. The study compared alprazolam with placebo and examined performance in different driving situations.
Overall lane-position variability was greater in the drug condition, and mean lane departures were approximately 54.7 versus 29.6 with placebo. The experiment therefore identified observable performance changes rather than merely documenting drug exposure.
The reported classification accuracy reached approximately 80% for outcomes defined from lane-position deviation and lane departures. It should not be presented as the sensitivity or specificity of an officer’s roadside examination. The researchers were developing a measurement approach within a small experimental dataset.
The analysis involved young participants and a simulator. Replication in larger and more varied populations, and evaluation outside the simulator, would be necessary before treating the approach as an established field instrument.
This paper can support discussion of specific driving tasks affected under the studied conditions. It cannot determine whether a particular driver was impaired from a positive drug result alone. Identify the administered drug, study population, task, and classification endpoint when explaining what the experiment contributes.
Original analysis of the supplied paper: Behavioral and Neurophysiological Signatures of Benzodiazepine Related Driving Impairments. Paper identifier: PMC4659917.